(Q49072224)

http://europepmc.org/abstract/MED/24006277

18 February 2018

meta-analysis

0 references

title

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. (English)

1 reference

http://europepmc.org/abstract/MED/24006277

18 February 2018

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Nicola De Stefano

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Douglas L Arnold

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

2 January 2014

1 reference

http://europepmc.org/abstract/MED/24006277

18 February 2018

published in

Annals of Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

43-49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

12 June 2020

cites work

1 reference

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

21 January 2018

1 reference

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

21 January 2018

1 reference

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

21 January 2018

1 reference

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

21 January 2018

1 reference

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

21 January 2018

1 reference

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

21 January 2018

1 reference

Normalized accurate measurement of longitudinal brain change.

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

Dehydration confounds the assessment of brain atrophy

21 January 2018

1 reference

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

21 January 2018

1 reference

Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.24018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24006277%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference